New platinum compound shows promise in tumor cells

December 7, 2009
A diagram of cisplatin.

(PhysOrg.com) -- MIT chemists have developed a new platinum compound that is as powerful as the commonly used anticancer drug cisplatin but better able to destroy tumor cells.

The new compound, mitaplatin, combines cisplatin with another compound, dichloroacetate (DCA), which can alter the properties of selectively in . Cancer cells switch their mitochondrial properties to change the way they metabolize glucose compared to normal cells, and DCA specifically targets the altered mitochondria, leaving normal cells intact.

"This differential effect conveys on mitaplatin the ability to kill cancer cells selectively in a co-culture with normal fibroblast cells, the latter being unaffected at the doses that we apply," says Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry.

The chemists designed mitaplatin so that when it enters a cell, it releases cisplatin and two units of DCA by intracellular reduction. Therefore, mitaplatin can attack nuclear DNA with cisplatin and mitochondria with DCA. DCA promotes the release of cell-death-promoting factors from the mitochondria, enhancing the cancer cell-killing abilities of cisplatin.

Lippard's laboratory has shown that in rodents, mitaplatin can be tolerated at much higher doses than cisplatin, and they have begun studies in mice transplanted with human tissues. If those results are promising, the researchers plan more studies for further demonstration of mitaplatin's ability in cancer therapy.

More information: "Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate," Shanta Dhar and Stephen Lippard. , week of Dec. 7, 2009.

Source: Massachusetts Institute of Technology (news : web)

Explore further: MIT researchers see alternative to common colorectal cancer drug

Related Stories

Small molecule offers big hope against cancer

January 16, 2007

DCA is an odourless, colourless, inexpensive, relatively non-toxic, small molecule. And researchers at the University of Alberta believe it may soon be used as an effective treatment for many forms of cancer.

Recommended for you

Scientists develop first catalysed reaction using iron salts

January 20, 2017

Scientists at the University of Huddersfield have developed a new chemical reaction that is catalysed using simple iron salts – an inexpensive, abundant and sustainable alternative to costlier and scarcer metals. The research ...

Chemists cook up new nanomaterial and imaging method

January 20, 2017

A team of chemists led by Northwestern University's William Dichtel has cooked up something big: The scientists created an entirely new type of nanomaterial and watched it form in real time—a chemistry first.

Gecko inspired adhesive can attach and detach using UV light

January 19, 2017

(Phys.org)—A small team of researchers at Kiel University in Germany has developed new technology that emulates the way a gecko uses its toes to cling to flat surfaces. In their paper published in the journal Science Robotics, ...

Treated carbon pulls radioactive elements from water

January 19, 2017

Researchers at Rice University and Kazan Federal University in Russia have found a way to extract radioactivity from water and said their discovery could help purify the hundreds of millions of gallons of contaminated water ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Birger
not rated yet Dec 08, 2009
The University of Alberta is progressing with tests of DCA for cancer treatment, but since it is an "orphan drug" they have to rely on donations - the pharmaceutical companies have no economic incentive to invest in research of a substance that cannot be patented.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.